Plasma lysophosphatidylcholine levels

Potential biomarkers for colorectal cancer

Zhenwen Zhao, Yijin Xiao, Paul Elson, Haiyan Tan, Sarah J. Plummer, Michael Berk, Phyu P. Aung, Ian C. Lavery, Jean P. Achkar, Li Li, Graham Casey, Yan Xu

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Purpose: Plasma levels of lysophospholipids were evaluated as potential biomarkers for colorectal cancer (CRC), where a highly reliable and minimally invasive blood test is lacking. Patients and Methods: Patients with CRC (n = 133) and control subjects (n = 125) were recruited through the Cleveland Clinic. Preoperative plasma samples were analyzed for lysophospholipid levels using liquid chromatography mass spectrometry in a blinded fashion. Participants were randomly divided in a 2:1 ratio into a "training set" (TS) and a "validation set" (VS). Logistic regression models were used in the TS to identify markers that best discriminated between CRC and controls. A cutoff point for the final discriminating model was developed using the receiver operating characteristic curve to achieve 95% specificity. All analyses were then independently validated in the VS. Results: Plasma levels of several lysophosphatidylcholines (LPCs), including 18:1- and 18:2-LPC, were significantly decreased in CRC patients compared with controls (P <.001). A model based on total saturated LPC and the difference between the proportional amounts of 18:2-LPC and 18:1-LPC in the unsaturated LPC fraction was derived from the TS. This model achieved a sensitivity and specificity of 82% and 93%, respectively, in the VS. Overall, 118 (94%) of 125 control subjects and 113 (85%) of 133 CRC cases were correctly identified, including eight (89%) of nine CRC cases with stage T1 disease. Conclusion: Percentage of 18:1-LPC or 18:2-LPC plasma levels compared with total saturated LPC levels, either individually or in combination, may represent potential biomarkers for CRC.

Original languageEnglish (US)
Pages (from-to)2696-2701
Number of pages6
JournalJournal of Clinical Oncology
Volume25
Issue number19
DOIs
StatePublished - Jul 1 2007

Fingerprint

Lysophosphatidylcholines
Colorectal Neoplasms
Biomarkers
Lysophospholipids
Logistic Models
Hematologic Tests
ROC Curve
Liquid Chromatography
Mass Spectrometry
Sensitivity and Specificity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Plasma lysophosphatidylcholine levels : Potential biomarkers for colorectal cancer. / Zhao, Zhenwen; Xiao, Yijin; Elson, Paul; Tan, Haiyan; Plummer, Sarah J.; Berk, Michael; Aung, Phyu P.; Lavery, Ian C.; Achkar, Jean P.; Li, Li; Casey, Graham; Xu, Yan.

In: Journal of Clinical Oncology, Vol. 25, No. 19, 01.07.2007, p. 2696-2701.

Research output: Contribution to journalArticle

Zhao, Z, Xiao, Y, Elson, P, Tan, H, Plummer, SJ, Berk, M, Aung, PP, Lavery, IC, Achkar, JP, Li, L, Casey, G & Xu, Y 2007, 'Plasma lysophosphatidylcholine levels: Potential biomarkers for colorectal cancer', Journal of Clinical Oncology, vol. 25, no. 19, pp. 2696-2701. https://doi.org/10.1200/JCO.2006.08.5571
Zhao, Zhenwen ; Xiao, Yijin ; Elson, Paul ; Tan, Haiyan ; Plummer, Sarah J. ; Berk, Michael ; Aung, Phyu P. ; Lavery, Ian C. ; Achkar, Jean P. ; Li, Li ; Casey, Graham ; Xu, Yan. / Plasma lysophosphatidylcholine levels : Potential biomarkers for colorectal cancer. In: Journal of Clinical Oncology. 2007 ; Vol. 25, No. 19. pp. 2696-2701.
@article{51bf39a0f5c44b6696c1df0c77765784,
title = "Plasma lysophosphatidylcholine levels: Potential biomarkers for colorectal cancer",
abstract = "Purpose: Plasma levels of lysophospholipids were evaluated as potential biomarkers for colorectal cancer (CRC), where a highly reliable and minimally invasive blood test is lacking. Patients and Methods: Patients with CRC (n = 133) and control subjects (n = 125) were recruited through the Cleveland Clinic. Preoperative plasma samples were analyzed for lysophospholipid levels using liquid chromatography mass spectrometry in a blinded fashion. Participants were randomly divided in a 2:1 ratio into a {"}training set{"} (TS) and a {"}validation set{"} (VS). Logistic regression models were used in the TS to identify markers that best discriminated between CRC and controls. A cutoff point for the final discriminating model was developed using the receiver operating characteristic curve to achieve 95{\%} specificity. All analyses were then independently validated in the VS. Results: Plasma levels of several lysophosphatidylcholines (LPCs), including 18:1- and 18:2-LPC, were significantly decreased in CRC patients compared with controls (P <.001). A model based on total saturated LPC and the difference between the proportional amounts of 18:2-LPC and 18:1-LPC in the unsaturated LPC fraction was derived from the TS. This model achieved a sensitivity and specificity of 82{\%} and 93{\%}, respectively, in the VS. Overall, 118 (94{\%}) of 125 control subjects and 113 (85{\%}) of 133 CRC cases were correctly identified, including eight (89{\%}) of nine CRC cases with stage T1 disease. Conclusion: Percentage of 18:1-LPC or 18:2-LPC plasma levels compared with total saturated LPC levels, either individually or in combination, may represent potential biomarkers for CRC.",
author = "Zhenwen Zhao and Yijin Xiao and Paul Elson and Haiyan Tan and Plummer, {Sarah J.} and Michael Berk and Aung, {Phyu P.} and Lavery, {Ian C.} and Achkar, {Jean P.} and Li Li and Graham Casey and Yan Xu",
year = "2007",
month = "7",
day = "1",
doi = "10.1200/JCO.2006.08.5571",
language = "English (US)",
volume = "25",
pages = "2696--2701",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "19",

}

TY - JOUR

T1 - Plasma lysophosphatidylcholine levels

T2 - Potential biomarkers for colorectal cancer

AU - Zhao, Zhenwen

AU - Xiao, Yijin

AU - Elson, Paul

AU - Tan, Haiyan

AU - Plummer, Sarah J.

AU - Berk, Michael

AU - Aung, Phyu P.

AU - Lavery, Ian C.

AU - Achkar, Jean P.

AU - Li, Li

AU - Casey, Graham

AU - Xu, Yan

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Purpose: Plasma levels of lysophospholipids were evaluated as potential biomarkers for colorectal cancer (CRC), where a highly reliable and minimally invasive blood test is lacking. Patients and Methods: Patients with CRC (n = 133) and control subjects (n = 125) were recruited through the Cleveland Clinic. Preoperative plasma samples were analyzed for lysophospholipid levels using liquid chromatography mass spectrometry in a blinded fashion. Participants were randomly divided in a 2:1 ratio into a "training set" (TS) and a "validation set" (VS). Logistic regression models were used in the TS to identify markers that best discriminated between CRC and controls. A cutoff point for the final discriminating model was developed using the receiver operating characteristic curve to achieve 95% specificity. All analyses were then independently validated in the VS. Results: Plasma levels of several lysophosphatidylcholines (LPCs), including 18:1- and 18:2-LPC, were significantly decreased in CRC patients compared with controls (P <.001). A model based on total saturated LPC and the difference between the proportional amounts of 18:2-LPC and 18:1-LPC in the unsaturated LPC fraction was derived from the TS. This model achieved a sensitivity and specificity of 82% and 93%, respectively, in the VS. Overall, 118 (94%) of 125 control subjects and 113 (85%) of 133 CRC cases were correctly identified, including eight (89%) of nine CRC cases with stage T1 disease. Conclusion: Percentage of 18:1-LPC or 18:2-LPC plasma levels compared with total saturated LPC levels, either individually or in combination, may represent potential biomarkers for CRC.

AB - Purpose: Plasma levels of lysophospholipids were evaluated as potential biomarkers for colorectal cancer (CRC), where a highly reliable and minimally invasive blood test is lacking. Patients and Methods: Patients with CRC (n = 133) and control subjects (n = 125) were recruited through the Cleveland Clinic. Preoperative plasma samples were analyzed for lysophospholipid levels using liquid chromatography mass spectrometry in a blinded fashion. Participants were randomly divided in a 2:1 ratio into a "training set" (TS) and a "validation set" (VS). Logistic regression models were used in the TS to identify markers that best discriminated between CRC and controls. A cutoff point for the final discriminating model was developed using the receiver operating characteristic curve to achieve 95% specificity. All analyses were then independently validated in the VS. Results: Plasma levels of several lysophosphatidylcholines (LPCs), including 18:1- and 18:2-LPC, were significantly decreased in CRC patients compared with controls (P <.001). A model based on total saturated LPC and the difference between the proportional amounts of 18:2-LPC and 18:1-LPC in the unsaturated LPC fraction was derived from the TS. This model achieved a sensitivity and specificity of 82% and 93%, respectively, in the VS. Overall, 118 (94%) of 125 control subjects and 113 (85%) of 133 CRC cases were correctly identified, including eight (89%) of nine CRC cases with stage T1 disease. Conclusion: Percentage of 18:1-LPC or 18:2-LPC plasma levels compared with total saturated LPC levels, either individually or in combination, may represent potential biomarkers for CRC.

UR - http://www.scopus.com/inward/record.url?scp=34447545773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447545773&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.08.5571

DO - 10.1200/JCO.2006.08.5571

M3 - Article

VL - 25

SP - 2696

EP - 2701

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 19

ER -